Small heterodimer partner (SHP) is an atypical nuclear receptor expressed in heart that has been shown to inhibit the hypertrophic response. Here, we assessed the role of SHP in cardiac metabolism and inflammation. Mice fed a high-fat diet (HFD) displayed glucose intolerance accompanied by increased cardiac mRNA levels of Shp. In HL-1 cardiomyocytes, SHP overexpression inhibited both basal and insulin-stimulated glucose uptake and impaired the insulin signalling pathway (evidenced by reduced AKT and AS160 phosphorylation), similar to insulin resistant cells generated by high palmitate/high insulin treatment (HP/HI; 500 µM/100 nM). In addition, SHP overexpression increased Socs3 mRNA and reduced IRS-1 protein levels. SHP overexpression also induced Cd36 expression ( ̴ 6.2 fold; p<0.001) linking to the observed intramyocellular lipid accumulation.
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Small heterodimer partner (SHP) contributes to insulin resistance in cardiomyocytes
Ricardo Rodríguez 
Introduction
Insulin resistance increases the risk for heart failure, the leading cause of death in subjects with type 2 diabetes (DM2) [1] . The underlying mechanisms involved in the pathogenesis of diabetic cardiomyopathy (DCM) include disturbances in myocardial energy metabolism and a chronic low-grade inflammatory process in cardiac tissue. Diabetic hearts are unresponsive to insulin-stimulation of glucose uptake, whereas (long-chain) fatty acid uptake and utilization are increased. This greater fatty acid influx exceeds the mitochondrial β-oxidative capacity [2] , leading to a gradual intramyocellular build-up of inert triacylglycerol stores and bioactive lipid metabolites (diacylglycerols, ceramides). The accumulation of these lipid intermediates in cardiomyocytes elicits insulin resistance, impairing both insulinstimulated glucose uptake [3] and oxidation [4] . Furthermore, elevated concentrations of these lipid intermediates have been linked to NF-κB activation [5] and aberrant cytokine production, which may explain the putative link between the onset of chronic low-grade inflammation and metabolic disorders. Over time, both excessive lipid accumulation and progressive insulin resistance in combination with inflammatory processes will gradually initiate a remodelling process in the heart, which at first appears to be a compensatory adaptation, thereafter fostering the development of a functional impairment, i.e., heart failure [1, 6] .
At the molecular level, nuclear receptors have emerged as relevant players in the regulation of gene expression profiles in metabolism and inflammation, not only acting as ligandactivated transcription factors, but also interfering with other gene expression regulators independent of their DNA-binding mechanisms. However, the role of nuclear receptors in the regulation of cardiac metabolism still remains partly uncharted. Small heterodimer partner (SHP) (NR0B2, according to the unified nomenclature system for the nuclear receptors [7] )
is an atypical nuclear receptor characterized by the lack of a DNA binding domain (DBD) [7] .
SHP predominantly acts by regulating the activity of other transcription factors through a number of different mechanisms [8] . Several studies have suggested the possible
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4 involvement of SHP in peripheral insulin resistance (for review see [9] ). In liver, SHP inhibits gluconeogenesis [10] [11] [12] [13] [14] [15] and improves insulin sensitivity through the inhibition of the signal transducer and activator of transcription 3 (STAT-3), and the expression of suppressor of cytokine signalling 3 (SOCS-3) [16] . In the heart, SHP expression blocks cardiac hypertrophy by interfering with GATA binding protein 6 (GATA6) signalling [17] . Concerning the role of SHP in the regulation of the inflammatory response, conflicting results have been reported in different contexts, i.e., SHP exerts anti-inflammatory effects [18] [19] [20] , and SHP takes part in NF-κB activation [21] [22] [23] [24] . In particular, the role of this nuclear receptor in cardiac glucose/lipid metabolism and inflammation is understudied.
Here, we report that SHP mRNA levels in heart positively correlate with glucose intolerance in high-fat diet (HFD)-fed mice, and that SHP overexpression in HL-1 cardiomyocytes results in insulin resistance and upregulation of the inflammatory processes, which therefore mimics the cellular responses induced by high-palmitate/high-insulin (HP/HI) treatment.
Material and methods
Reagents
2-deoxy-D-[
3 H]-deoxyglucose was obtained from GE Healthcare. Palmitate, insulin and bovine serum albumin (BSA) were purchased from Sigma.
Animals
Animal experiments were performed in a well-characterized model [25] [26] [27] . Five-week-old CD-1 male mice were maintained on a standard light-dark cycle (12 h light/dark cycle) and temperature (21±1ºC) conditions, with ad libitum access to food and water. Animals were randomly distributed in two experimental groups (n = 5 each) and fed with a standard chow diet (STD; Harlan Ibérica S.A.) or a high-fat diet (HFD; 35% fat by weight, 58% kcal from fat;
Harlan Ibérica S.A.) for 3 weeks. Before the end the procedure, a glucose tolerance test was performed on mice fasted for 4 h. Briefly, animals received 2 g/kg body weight of glucose by A C C E P T E D M A N U S C R I P T , 2 mmol/l L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin). Rat cardiomyocytes were isolated using a Langendorff perfusion system, as previously described [28] and seeded in laminin coated plates. After 90 min adhesion in modified Krebs-Ringer medium [28] , cells were cultured according to the method described by Volz et al. [29] in modified serum-free medium M199
supplemented with 5 mM creatine monohydrate, 3.2 mM carnitine hydrochloride, 3.1 mM taurine, 100 units/ml penicillin and 10 mg/ml streptomycin. Both HL-1 cells and primary rat cardiomyocytes were maintained at 37°C and 5% CO 2 . Cells were seeded in multi-well plates and transduced for 48 h with adenoviral particles at a multiplicity of infection (MOI) of 50, as previously described [14] . SHP over-expression was verified by real-time PCR.
Alternatively, non-transduced cells were serum deprived in Dulbecco's Modified Eagle Medium (DMEM; supplemented with 2 mM L-glutamine, 100 µM non-essential amino acids (NEAA), 100 U/ml penicillin and 100 µg/ml streptomycin) for 24 h, and then challenged with high palmitate (500 µM, palmitate:BSA 3:1)/high insulin (100 nM) (HP/HI) for 16 h.
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6 HEK 293T (used to amplify and titrate adenovirus) were cultured in DMEM supplemented with 10% FCS, 2 mM L-glutamine and antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin).
Preparation of Recombinant Adenovirus
For ectopic expression of SHP, adenoviral delivery system was used. Adenoviruses H in a β-counter.
Immunoblotting
A C C E P T E D M A N U S C R I P T Western blot images were analysed with a Molecular Imager (ChemiDoc XRS, BioRad) and quantified with Quantity One® (BioRad).
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Oil-Red-O staining
Lipid content was measured in HL-1 transduced with adenoviral particles using the Oil-Red-O staining. Cells were fixed in ice-cold 4% paraformaldehyde for 15 min and stained with fresh
Oil-Red-O (Sigma) solution for 30 min. Nuclei were counterstained with Haematoxylin and cells were mounted with Faramount mounting medium (Dako) after extensive washing.
Pictures were taken at 40X magnification with a Nikon digital camera DMX1200 and ACT-1 v2.63 software from Nikon Corporation. The lipid content was quantified by Image J software from five random fields of three different experiments.
RNA preparation and quantitative real time reverse transcription-polymerase chain reaction (RT-PCR) analysis
Levels of mRNA were assessed by the real time RT-PCR as previously described [31] . Total RNA was isolated using the TRI Reagent (Sigma, Saint Louis, USA) according to the manufacturer's recommendations. RNA integrity was determined by electrophoresis in agarose gel. Total RNA (1 µg) was reverse-transcribed using the iScript TM cDNA Synthesis Kit (BioRad). Levels of mRNA were assessed by real-time PCR on an ABI PRISM 7900 sequence detector (Applied Biosystems). Primers for SYBR Green real-time PCR analysis are listed in Table 1 . Cyclophilin A was used as endogenous control.
Mitochondrial inner membrane potential
The mitochondrial inner membrane potential were determine using the reagent MitoTracker
Red CMXRos (Invitrogen), following the manufacturer's instructions.
ATP measurement
Cellular ATP levels were determined using Cell-Titer-Glo® assay (Promega) according to manufacturer's instructions.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were obtained as previously described [32] from HL-1 cells transduced with adenoviral particles. Protein concentration was measured by the BCA protein assay TM .
EMSA was performed using 5 µg of nuclear extracts and a double-stranded DNA probe containing the consensus binding site for NF-κB (5'-AGTTGAGGGGACTTTCCCAGGC-3'; Promega). DNA probe was labelled with [γ-32 P]-ATP by using T4 polynucleotide kinase (Invitrogen) and purified on a Sephadex G-50 column (GE Healthcare). Competition assays were performed by adding an excess of unlabelled probe. Protein-DNA complexes were resolved by electrophoresis at 4ºC on 5% polyacrylamide gels. Gels were dried and subjected to autoradiography using a Storage Phosphor Screen (GE Healthcare). Shifted bands were detected using a Personal Molecular Imager™ System (Bio-Rad).
Co-immunoprecipitation
Cell nuclear extracts were brought to a final volume of 0.5 mL with IP buffer containing 20 mM
Tris, 137 mM NaCl, 2 mM EDTA, 10% glycerol 1% Igepal for 6 h at 4 ºC and incubated with 4 µg of anti-p65 or an IgG of the same isotope (antibodies from Santa Cruz). Samples were incubated overnight at 4ºC with protein A-agarose, and agarose beads were collected by centrifugation. Then, pellets were washed with immunoprecipitation (IP) buffer containing protease inhibitors, resuspended in SDS-PAGE sample buffer and boiled for 5 min at 100 ºC.
The resulting supernatant was then subjected to electrophoresis on 10% SDS-PAGE and immunoblot analysis.
Statistical Analyses
Results are expressed as mean ± standard deviation (SD). Significant differences were established by Student's t-test. The correlation between two variables was evaluated using Spearman's correlation coefficient. All data were analysed by using the GraphPad Instat programme (GraphPad Software V2.03). Differences were considered significant at p<0.05.
Results
Shp mRNA levels are induced in heart from mice fed with HFD
To explore whether glucose intolerance may be related to changes in cardiac Shp expression, we used hearts from animals in which glucose intolerance was induced by HFD [25] . Interestingly, Shp mRNA levels were up-regulated in hearts from HFD-fed mice compared to animals fed with a chow diet ( ̴ 1.4 fold, p<0.05) ( Figure 1A ), and positively correlated to the AUC values from the glucose tolerance test (r=0.6848, p<0.05) ( Figure 1B) .
Therefore, the data suggest that HFD-induced SHP upregulation may either be an innocent secondary effect or directly contribute to the development of cardiac insulin resistance. To further evaluate key downstream factors involved in glucose metabolism, the expression of G6p, Pepck, Glut4 and Pdk4 were analysed, finding a slight but significant reduction (18% reduction, p<0.05) in the Glut4 mRNA levels in the hearts from HFD-fed mice ( Figure 1C ).
SHP overexpression impairs glucose uptake and insulin signalling
To of Socs3, a protein involved in the inhibition of insulin signalling [33] , was evaluated. In line with our expectations, SHP over-expression enhanced Socs3 mRNA levels ( ̴ 1.7-fold, p<0.05) ( Figure 3A ). SOCS3 promotes IRS-1 proteasomal degradation [34] . Accordingly, we found a reduction in the IRS-1 protein levels in SHP overexpressing cells ( Figure 3B ).
Altogether, these results show that both SHP overexpression and HP/HI exposure each lead to insulin resistance in cardiac myocytes.
SHP overexpression enhances intramyocellular lipid storage
Because insulin resistance and decreases in insulin-stimulated glucose uptake are closely Acot1 expression encoding for acyl-CoA thioesterase 1 (data not shown), which hydrolyses fatty acyl-CoAs to free fatty acids and CoA. Lipid storage is often due to increased fatty acid uptake exceeding mitochondrial β-oxidation capacity [2] . Furthermore, SHP overexpression affected the expression of specific genes involved in fatty acid metabolism. Thus, no changes were found in the mRNA levels of Cpt1b ( Figure 5A ), which catalyses the entry of long-chain fatty acids into the mitochondrial matrix. Interestingly, Acaca was reduced in SHP overexpressing cells (42%, p<0.05) ( Figure 5A ). In addition, the Acaca protein product, ACC,
showed enhanced phosphorylation in SHP overexpressing cells ( Figure 5B ). Once ACC is phosphorylated, the production of the allosteric CPT1B inhibitor malonyl-CoA is reduced,
indicating an increased flux of fatty acids into mitochondria. Once inside mitochondria, fatty acyl-thioesters can undergo β-oxidation through enzymes including Acox1 or Acadvl.
Therefore, we evaluated the expression of these genes in SHP overexpressing cells.
Whereas SHP overexpression did not induce changes in the Acox1 mRNA levels, it significantly raised Acadvl expression ( ̴ 1.8 fold; p<0.05) ( Figure 5A ).
SHP over-expression impairs mitochondrial function
Once long-chain and very-long-chain fatty acids are oxidized, they provide reducing equivalents (NADH) which are metabolized in the respiratory chain, resulting in the generation of an electrochemical gradient of protons, generally used to produce ATP via oxidative phosphorylation [35] . Nevertheless, under some circumstances, ATP synthesis can be impaired because of the proton electrochemical gradient dissipation through the UCPs, placed in the inner mitochondrial membrane [36] . To explore whether SHP overexpression may contribute to mitochondrial dysfunction, we determined the expression of Nrf1 and Nrf2, both involved in the control of DNA mitochondrial-encoded genes, such as the subunit 1 of complex I (NADH dehydrogenase subunit 1, ND1), as well as Nd1 and Ucp3. Despite no changes were found in Nrf1 and Nd1 mRNA levels, the expression of Nrf2 was up-regulated in SHP over-expressing cells ( Figure 6A ). Accordingly, SHP over-expression induced the protein levels of the succinate dehydrogenase complex iron sulfur subunit B Complex II (CII-SDHB) of the mitochondrial respiratory chain ( ̴ 4 fold, p<0.01) ( Figure 6B ), as well as the mitochondrial inner membrane potential ( Figure 6C ). Ucp3 mRNA levels were induced ( ̴ 2.9
fold, p<0.05) ( Figure 6A ), whereas ATP levels were reduced (34% reduction, p<0.001) in SHP over-expressing cells.
SHP overexpression induced NF-κB activation in cardiomyocytes
Intramyocellular lipid storage may activate Ser/Thr-kinase cascades, activating the proinflammatory transcription factor NF-κB [5] , and thereby linking the low-grade inflammatory process with metabolic disorders, such as insulin resistance. To explore whether the SHP- 
Decreased p65-PPARα interaction in SHP over-expressing cells
Metabolism and inflammation both are regulated by peroxisome proliferator-activated receptors (PPARs) in cardiomyocytes [26, [37] [38] [39] . Interestingly, alterations in the cardiac expression of PPARs are related to cardiac lipotoxicity, contributing to metabolic
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13 disturbances related to insulin resistance and diabetic heart [40] [41] [42] [43] [44] [45] . Therefore, we explored the PPAR gene expression profile in SHP overexpressing cells. As is shown in Figure 8A , SHP overexpression did not affect the mRNA levels of Ppard. However, SHP overexpression reduced the Ppara expression (79% reduction, p<0.001) and strongly induced the Pparg mRNA levels ( ̴ 58-fold induction, p<0.001) ( Figure 8A ), together reflecting a similar profile to that found in the diabetic heart.
Finally, we further investigated the molecular mechanism by which SHP overexpression increases NF-κB activation in cardiac cells. PPAR activities are generally reduced by NF-κB activation [38, 44] . Vice versa, PPARα may inhibit NF-κB signalling through different mechanisms, including physical interaction between PPARα and the p65 subunit of NF-κB [46] . In order to evaluate whether the reduction in PPARα expression may affect its interaction with NF-κB in SHP overexpressing cells, we performed co-immunoprecipitation assays. Isolated nuclear extracts were immunoprecipitated using antibodies against the p65 subunit of NF-κB, subjected to SDS-PAGE, and immunoblotted with antibodies against PPARα. SHP overexpression strongly reduced the physical interaction between p65 and PPARα ( Figure 7B ), suggesting that dissociation of the PPARα-NF-κB protein complex may enable NF-κB transactivation and the development of the inflammatory response seen in SHP overexpressing cells.
Discussion
DM2 related alterations are especially relevant in the heart, because the myocardium needs to produce energy constantly, using both glucose and fatty acids, in order to maintain proper cardiac function. Despite advances in DM2 research, the prevalence of this disease is steadily rising worldwide [47] . The lack of an effective therapy for DM2 and its related disturbances such as DCM are alarming. Therefore, it is necessary to identify new emerging molecular targets for the potential treatment of the diabetic heart. In the present study, we found that SHP, an atypical nuclear receptor involved in the regulation of peripheral insulin resistance [9] , was induced in hearts from mice fed with a HFD and which displayed glucose intolerance compared with animals fed with a chow diet [25] . Hearts from these animals did not show changes in the expression of genes involved in gluconeogenesis, but yes a slight but significant reduction in Glut4 mRNA levels. Interestingly, cardiac SHP deficiency induces cardiac hypertrophy [17] . Given that during cardiac hypertrophy there is a shift in the substrate preference by heart, from fatty acids to glucose [48] [49] [50] , these animals could show an increase in glucose utilization. However, the short period of feeding with HFD probably did not cause any structural changes or functional derangements in our animal model. These novel observations suggest that the induction of cardiac Shp expression after the HFD challenge could be related to the onset of the heart metabolic dysregulation mediated by the dietary fat. This hypothesis was further supported by subsequent data showing a positive correlation between the cardiac Shp mRNA levels and glucose intolerance, as measured by the AUC from the glucose tolerance test. Therefore, to explore the mode of action of SHP in cardiac metabolism we overexpressed this nuclear receptor in HL-1 cardiomyocytes.
At the cellular level, we demonstrate for the first time that SHP overexpression mimics the insulin resistance response elicited by a combination of HP/HI exposure in cardiomyocytes.
It has been previously shown that in liver, SHP inhibits gluconeogenesis [10] [11] [12] [13] [14] [15] 51] and improves insulin sensitivity [16] promoting the glucose delivery to mitochondria [13] .
However, our data revealed that in HL-1 cardiomyocytes, SHP overexpression reduced both basal and insulin-stimulated glucose uptake, in similar degrees to those found in HP/HI challenged cells. In agreement with this, the insulin signalling pathway, analysed by AKT and AS160 phosphorylation, was also impaired in both models of cardiac insulin resistance.
Insulin resistance was further analysed determining the expression of Socs3 [33] . Despite it has been previously shown that in hepatocytes SHP improves insulin sensitivity via inhibition of the STAT-3/SOCS-3 pathway [16] , Socs3 mRNA levels were induced in SHP overexpressing cells. This data was in line with increased Socs1 and Socs3 expression found in
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heart from HFD-fed mice [26] . Insulin resistance is commonly linked to intramyocellular lipid accumulation [52] . The increase in lipid mediators has been associated with cardiac dysfunction [53, 54] , and vice versa cardiac function improved with their reduction [53] . According to the observed role of SHP as an originator of insulin resistance, we found increased lipid droplets in SHP over- Reduction in the mRNA levels of Acaca and the up-regulation of Acadvl and Ucp3 in SHP over-expressing cells indicated a reprogramming in the expression of genes involved in fatty acid β-oxidation. Notably, increased Ucp3 activity in skeletal muscle has been associated with increased fatty acid oxidation rates [55] . However, because the heart needs to produce energy constantly, induction of Ucp3 expression has been previously reported in diabetic hearts as a hallmark of contractile dysfunction [56] . The induction of Ucp3 mRNA level was in parallel with decreased ATP levels in SHP over-expressing cells, which may reflect that increased fatty acid oxidation and mitochondrial respiration are less efficient for energy production upon Ucp3 induction [57] .
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Intramyocellular lipid accumulation is associated with the activation of the pro-inflammatory transcription factor NF-κB and abnormal cytokine production, thereby linking metabolic disorders with a low-grade inflammatory process [5] . Interestingly, recent work indicated a role of SHP in the inflammatory response, although results were somewhat conflicting.
Indeed, while SHP was firstly described as transcriptional co-activator of NF-κB in several cell types [21] [22] [23] [24] , data from others support an anti-inflammatory role for this nuclear receptor [18] [19] [20] . Specifically, the molecular mechanisms by which SHP drives its antiinflammatory effects involved dual regulatory functions in a canonical transcription factor NF-κB signalling pathway, acting as both a repressor of transactivation of the NF-κB subunit p65
and an inhibitor of polyubiquitination of the adaptor TRAF6 [20] . Thus, SHP may be considered as a modifier, able to differentially regulate the transcriptional activity of the same transcription factor, such as NF-κB, in function of the cell requirements. To clarify the role of SHP in cardiac inflammation we explored the degree of NF-κB activation. In accordance with a pro-inflammatory action, SHP over-expression induced the NF-κB DNA-binding activity, as well as the mRNA levels of Il6 and Tnf, two well-known NF-κB target genes involved in the heart failure progression [58] . Interestingly, a similar pro-inflammatory profile, characterized by increased Il6 and Tnf expression and an enhanced NF-κB DNA-binding activity, was found in the hearts from HFD-fed mice [26] , where we observed increased Shp expression.
As a result, our data indicates a contribution of SHP to NF-κB activation, and support a proinflammatory role of SHP, at least in cardiomyocytes.
PPARs have been proposed as potential modulators of both fatty acid metabolism [37, 38, 44] and inflammation [26, [37] [38] [39] in cardiomyocytes. Indeed, changes in the expression/activity of these transcription factors have been previously described in hearts with metabolic disturbances. Our data revealed that SHP overexpression strongly reduced Ppara mRNA levels. This data agrees with the Ppara reduction found in cardiomyocytes A C C E P T E D M A N U S C R I P T chronically exposed to fatty acid excess [43] and in hearts from senescence-accelerated mice with enhanced ceramide levels [44] . Both Ppara and Ppard are expressed in comparable levels in heart and share similar functions in cardiomyocytes regarding fatty acid metabolism [59] . Despite the observed reduction of Ppara expression, no changes were observed in the expression of Ppara target-genes, such as Cpt1b. However, it was previously reported that PPARδ can compensate for the lack of PPARα [60] , which is consistent with our data showing unaltered Ppard expression in SHP overexpressing cells.
Unlike other PPARs, Pparg is barely detectable in heart, but it is up-regulated in hearts from rat models of DM2 [41, 42, 45] , thereby contributing to the storage of intramyocellular lipid content [45] . In agreement with this, SHP overexpression strongly induced Pparg, which is in line with the induction of its target gene Cd36, setting a potential bridge between changes in
Pparg expression and the increased in lipid droplets observed in SHP overexpressing cells.
Reduced Pparg and Cd36 expression recently have been found in liver from Shp-deficient mice [61] , thus suggesting a direct link between SHP and the regulation of the Pparg expression. The molecular mechanisms underlying such regulation may involve SHPmediated FXR activation [62] and HNF4α activation by RAR/Hes6 inhibition [63] . In addition, SHP may act as endogenous enhancer of PPARγ transactivation through a mechanism involving a competition with the nuclear receptor corepressor (NCoR) for the direct binding to PPARγ [64] . However, while SHP acts as endogenous enhancer of PPARγ transactivation [64] , it can activate or repress the PPARα transcriptional activity [65] , suggesting the involvement of additional factors in the SHP-mediated transcriptional regulation of PPARs.
It has been previously reported that PPARα may act through DNA-binding independent mechanisms that involves a physical interaction of PPARα with NF-κB [46] . This association prevents NF-κB from binding to its response element, thereby inhibiting its ability to induce gene transcription [46] . Here, we demonstrate that SHP overexpression reduced proteinprotein association between PPARα and p65, suggesting that dissociation between these two proteins is one of the mechanisms by which SHP overexpression drives NF-κB activation and the inflammatory response in cardiomyocytes.
In summary, in the present study we show for the first time that ectopic expression of SHP in HL-1 cardiomyocytes induces the accumulation of intramyocellular lipid droplets and changes the expression of genes related to lipid metabolism and mitochondrial uncoupling.
The SHP-induced lipid storage correlates to an inflammatory response involving the dissociation of PPARα from NF-κB and impairment of the insulin signalling pathway.
Although further studies are necessary to explore the role of cardiac SHP in the context of normal physiological stimuli, our data show the relevance of this nuclear receptor in processes that have been linked to cardiac dysfunction, suggesting this nuclear receptor as a new potential therapeutic target for DCM. 
